<p>Van ECK Associates Corp 在最近向證券交易委員會的披露中表示，在第四季度將其在西氏醫藥服務公司（NYSE:WST - 免費報告）的持股減少了 49.7%。該公司在季度內出售了 708,792 股後，持有 716,087 股這家醫療器械供應商的股票。Van ECK Associates Corp 在最近一個季度末持有西氏醫藥服務 1.00% 的股份，價值為 197,025,000 美元。</p>
<ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
<p>其他機構投資者也對該公司的持倉進行了調整。Holocene Advisors LP 在第三季度新購入了價值 49,085,000 美元的西氏醫藥服務股份。Nordea Investment Management AB 在第四季度將其在西氏醫藥服務的持倉提高了 42.7%。Nordea Investment Management AB 目前持有 14,950 股這家醫療器械供應商的股票，價值為 4,122,000 美元，此前在上個季度又購買了 4,477 股。摩根大通在第三季度將其在西氏醫藥服務的持倉提高了 7.7%。摩根大通目前持有 236,963 股這家醫療器械供應商的股票，價值為 62,163,000 美元，此前在上個季度又收購了 16,919 股。Birch Hill Investment Advisors LLC 在第四季度將其在西氏醫藥服務的持倉提高了 11.5%。Birch Hill Investment Advisors LLC 目前持有 152,148 股這家醫療器械供應商的股票，價值為 41,862,000 美元，此前在上個季度又收購了 15,678 股。最後，DAVENPORT &amp; Co LLC 在第四季度將其在西氏醫藥服務的持倉提高了 559.8%。DAVENPORT &amp; Co LLC 目前持有 9,521 股這家醫療器械供應商的股票，價值為 2,620,000 美元，此前在上個季度又收購了 8,078 股。93.90% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>WST 最近成為幾份分析師報告的主題。Evercore 在 4 月 24 日的報告中重申了對西氏醫藥服務的 “跑贏大盤” 評級。Wolfe Research 在 6 月 1 日的報告中開始覆蓋西氏醫藥服務的股票。他們對該股票設定了 “跑贏大盤” 評級和 375.00 美元的目標價。巴克萊在週二的報告中將西氏醫藥服務的評級從 “持平” 上調至 “增持”，並將其目標價從 310.00 美元提高至 400.00 美元。Zacks Research 在 5 月 13 日的報告中將西氏醫藥服務的評級從 “持有” 上調至 “強烈買入”。最後，Weiss Ratings 在 4 月 27 日的研究報告中將西氏醫藥服務的評級從 “持有（c-）” 上調至 “持有（c）”。兩位研究分析師給予該股票 “強烈買入” 評級，十位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “買入”，平均目標價為 340.09 美元。</p>
<ul>
<li>今年將推動 S&amp;P 500 表現的因素是什麼？</li>
</ul>
<p><strong>查看我們對 WST 的最新分析</strong></p>
<h2>西氏醫藥服務股票表現</h2>
<p>NYSE:WST 週五開盤價為 328.33 美元。西氏醫藥服務公司過去 12 個月的最低價為 206.80 美元，最高價為 336.82 美元。該公司的流動比率為 2.71，速動比率為 2.04，債務與股本比率為 0.07。該公司的 50 日移動平均線為 298.97 美元，200 日移動平均線為 271.63 美元。該公司的市值為 232 億美元，市盈率為 43.89，市盈增長比率為 2.76，貝塔值為 1.18。</p>
<ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
<p>西氏醫藥服務（NYSE:WST - 獲取免費報告）在 4 月 23 日星期四發佈了季度財報。這家醫療器械供應商報告本季度每股收益為 2.13 美元，超出市場共識預期的 1.68 美元，超出幅度為 0.45 美元。西氏醫藥服務的淨利潤率為 16.85%，股本回報率為 19.03%。該公司本季度的收入為 8.449 億美元，而分析師預期為 7.7968 億美元。去年同期，該公司的每股收益為 1.45 美元。該公司本季度的收入同比增長 21.0%。西氏醫藥服務已將其 2026 財年的指引設定為每股收益 8.400-8.750 美元，2026 年第二季度的指引為每股收益 2.050-2.120 美元。分析師預測西氏醫藥服務公司在當前財年將發佈每股收益 8.6 美元。</p>
<p>西氏醫藥服務宣佈其董事會已於 2 月 17 日授權了一項股票回購計劃，允許公司回購價值 10 億美元的流通股。該回購授權允許這家醫療器械供應商通過公開市場購買最多 5.6% 的股份。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
<h2>內部活動</h2>
<p>在其他西氏醫藥服務的新聞中，副總裁安妮特·F·費沃瑞特於 4 月 27 日星期一出售了 2,817 股該公司的股票。股票以平均價格 305.20 美元出售，總價值為 859,748.40 美元。交易完成後，副總裁直接持有該公司 16,828 股股票，價值 5,135,905.60 美元。這筆交易代表了他們持股比例的 14.34% 的減少。該出售在向 SEC 的文件中披露，相關信息可通過此鏈接獲取。此外，首席會計官查德·温特斯於 4 月 27 日星期一出售了 896 股該公司的股票。股票以平均價格 300.67 美元出售，總交易額為 269,400.32 美元。交易完成後，首席會計官持有 1,523 股公司的股票，價值約 457,920.41 美元。這筆交易代表了他們持股比例的 37.04% 的減少。該出售的 SEC 文件提供了更多信息。公司內部人士持有公司股票的 0.60%。</p>
<h2>西氏醫藥服務公司簡介</h2>
<p>（免費報告）</p>
<p>西氏醫藥服務公司是一家全球開發和製造組件、系統及服務的公司，旨在實現可注射藥物的封裝和輸送。該公司專注於為製藥和生物技術行業提供高質量的包裝和輸送解決方案，生產用於疫苗、生物製劑和其他可注射療法的主要藥物包裝組件和專用藥物輸送設備。西氏以其保持無菌性和與敏感藥物配方兼容的彈性密封件、密封圈和聚合物組件而聞名。</p>
<p>除了組件製造，西氏還提供工程化輸送系統和產品生命週期支持服務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過西氏醫藥服務</li>
<li>TJX：零售業的頂級掠食者在通貨膨脹中大快朵頤</li>
<li>MarketBeat 週迴顧 – 06/08 - 06/12</li>
<li>SpaceX 敲響鐘聲，打破所有記錄</li>
<li>Adobe 股票剛剛變得更便宜——華爾街是否忽視了這個故事？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
<p>在考慮西氏醫藥服務之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而西氏醫藥服務並不在名單上。</p>
<p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西氏醫藥服務

摩根大通

JPMO

<p>Van ECK Associates Corp 在第四季度將其對西氏醫藥服務（WST）的持股減少了 49.7%，目前保留 716,087 股，價值 1.97 億美元。其他機構如 Nordea 和摩根大通則增加了他們的持股。分析師們維持了一致的 “買入” 評級，平均目標價為 340.09 美元。WST 最近公佈了強勁的第一季度財報，收益超出預期，每股收益為 2.13 美元，營收為 8.449 億美元，同比增長 21%</p>

<p>Van ECK Associates Corp reduced its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 49.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 716,087 shares of the medical instruments supplier's stock after selling 708,792 shares during the quarter. Van ECK Associates Corp owned 1.00% of West Pharmaceutical Services worth $197,025,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Van ECK Associates Corp 在最近向證券交易委員會的披露中表示，在第四季度將其在西氏醫藥服務公司（NYSE:WST - 免費報告）的持股減少了 49.7%。該公司在季度內出售了 708,792 股後，持有 716,087 股這家醫療器械供應商的股票。Van ECK Associates Corp 在最近一個季度末持有西氏醫藥服務 1.00% 的股份，價值為 197,025,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
</div><p>Other institutional investors have also made changes to their positions in the company. Holocene Advisors LP acquired a new position in shares of West Pharmaceutical Services during the third quarter worth $49,085,000. Nordea Investment Management AB lifted its position in shares of West Pharmaceutical Services by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier's stock worth $4,122,000 after purchasing an additional 4,477 shares in the last quarter. JPMorgan Chase &amp; Co. raised its holdings in West Pharmaceutical Services by 7.7% in the third quarter. JPMorgan Chase &amp; Co. now owns 236,963 shares of the medical instruments supplier's stock valued at $62,163,000 after acquiring an additional 16,919 shares in the last quarter. Birch Hill Investment Advisors LLC raised its holdings in West Pharmaceutical Services by 11.5% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier's stock valued at $41,862,000 after acquiring an additional 15,678 shares in the last quarter. Finally, DAVENPORT &amp; Co LLC raised its holdings in West Pharmaceutical Services by 559.8% in the fourth quarter. DAVENPORT &amp; Co LLC now owns 9,521 shares of the medical instruments supplier's stock valued at $2,620,000 after acquiring an additional 8,078 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他機構投資者也對該公司的持倉進行了調整。Holocene Advisors LP 在第三季度新購入了價值 49,085,000 美元的西氏醫藥服務股份。Nordea Investment Management AB 在第四季度將其在西氏醫藥服務的持倉提高了 42.7%。Nordea Investment Management AB 目前持有 14,950 股這家醫療器械供應商的股票，價值為 4,122,000 美元，此前在上個季度又購買了 4,477 股。摩根大通在第三季度將其在西氏醫藥服務的持倉提高了 7.7%。摩根大通目前持有 236,963 股這家醫療器械供應商的股票，價值為 62,163,000 美元，此前在上個季度又收購了 16,919 股。Birch Hill Investment Advisors LLC 在第四季度將其在西氏醫藥服務的持倉提高了 11.5%。Birch Hill Investment Advisors LLC 目前持有 152,148 股這家醫療器械供應商的股票，價值為 41,862,000 美元，此前在上個季度又收購了 15,678 股。最後，DAVENPORT &amp; Co LLC 在第四季度將其在西氏醫藥服務的持倉提高了 559.8%。DAVENPORT &amp; Co LLC 目前持有 9,521 股這家醫療器械供應商的股票，價值為 2,620,000 美元，此前在上個季度又收購了 8,078 股。93.90% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>WST has been the topic of several recent analyst reports. Evercore reaffirmed an &#34;outperform&#34; rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They set an &#34;outperform&#34; rating and a $375.00 target price on the stock. Barclays raised shares of West Pharmaceutical Services from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and increased their target price for the stock from $310.00 to $400.00 in a report on Tuesday. Zacks Research raised shares of West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, May 13th. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a &#34;hold (c-)&#34; rating to a &#34;hold (c)&#34; rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and an average price target of $340.09.</p>
<div class="lb-trans"><p>WST 最近成為幾份分析師報告的主題。Evercore 在 4 月 24 日的報告中重申了對西氏醫藥服務的 “跑贏大盤” 評級。Wolfe Research 在 6 月 1 日的報告中開始覆蓋西氏醫藥服務的股票。他們對該股票設定了 “跑贏大盤” 評級和 375.00 美元的目標價。巴克萊在週二的報告中將西氏醫藥服務的評級從 “持平” 上調至 “增持”，並將其目標價從 310.00 美元提高至 400.00 美元。Zacks Research 在 5 月 13 日的報告中將西氏醫藥服務的評級從 “持有” 上調至 “強烈買入”。最後，Weiss Ratings 在 4 月 27 日的研究報告中將西氏醫藥服務的評級從 “持有（c-）” 上調至 “持有（c）”。兩位研究分析師給予該股票 “強烈買入” 評級，十位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “買入”，平均目標價為 340.09 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年將推動 S&amp;P 500 表現的因素是什麼？</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on WST</strong></p>
<div class="lb-trans"><p><strong>查看我們對 WST 的最新分析</strong></p>
</div><h2>West Pharmaceutical Services Stock Performance</h2>
<div class="lb-trans"><h2>西氏醫藥服務股票表現</h2>
</div><p>NYSE:WST opened at $328.33 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $206.80 and a twelve month high of $336.82. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average of $298.97 and a 200-day moving average of $271.63. The firm has a market cap of $23.20 billion, a price-to-earnings ratio of 43.89, a price-to-earnings-growth ratio of 2.76 and a beta of 1.18.</p>
<div class="lb-trans"><p>NYSE:WST 週五開盤價為 328.33 美元。西氏醫藥服務公司過去 12 個月的最低價為 206.80 美元，最高價為 336.82 美元。該公司的流動比率為 2.71，速動比率為 2.04，債務與股本比率為 0.07。該公司的 50 日移動平均線為 298.97 美元，200 日移動平均線為 271.63 美元。該公司的市值為 232 億美元，市盈率為 43.89，市盈增長比率為 2.76，貝塔值為 1.18。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. During the same quarter last year, the firm posted $1.45 EPS. The business's revenue for the quarter was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>西氏醫藥服務（NYSE:WST - 獲取免費報告）在 4 月 23 日星期四發佈了季度財報。這家醫療器械供應商報告本季度每股收益為 2.13 美元，超出市場共識預期的 1.68 美元，超出幅度為 0.45 美元。西氏醫藥服務的淨利潤率為 16.85%，股本回報率為 19.03%。該公司本季度的收入為 8.449 億美元，而分析師預期為 7.7968 億美元。去年同期，該公司的每股收益為 1.45 美元。該公司本季度的收入同比增長 21.0%。西氏醫藥服務已將其 2026 財年的指引設定為每股收益 8.400-8.750 美元，2026 年第二季度的指引為每股收益 2.050-2.120 美元。分析師預測西氏醫藥服務公司在當前財年將發佈每股收益 8.6 美元。</p>
</div><p>West Pharmaceutical Services declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued.</p>
<div class="lb-trans"><p>西氏醫藥服務宣佈其董事會已於 2 月 17 日授權了一項股票回購計劃，允許公司回購價值 10 億美元的流通股。該回購授權允許這家醫療器械供應商通過公開市場購買最多 5.6% 的股份。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of the firm's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Chad Winters sold 896 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company's stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他西氏醫藥服務的新聞中，副總裁安妮特·F·費沃瑞特於 4 月 27 日星期一出售了 2,817 股該公司的股票。股票以平均價格 305.20 美元出售，總價值為 859,748.40 美元。交易完成後，副總裁直接持有該公司 16,828 股股票，價值 5,135,905.60 美元。這筆交易代表了他們持股比例的 14.34% 的減少。該出售在向 SEC 的文件中披露，相關信息可通過此鏈接獲取。此外，首席會計官查德·温特斯於 4 月 27 日星期一出售了 896 股該公司的股票。股票以平均價格 300.67 美元出售，總交易額為 269,400.32 美元。交易完成後，首席會計官持有 1,523 股公司的股票，價值約 457,920.41 美元。這筆交易代表了他們持股比例的 37.04% 的減少。該出售的 SEC 文件提供了更多信息。公司內部人士持有公司股票的 0.60%。</p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西氏醫藥服務公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏醫藥服務公司是一家全球開發和製造組件、系統及服務的公司，旨在實現可注射藥物的封裝和輸送。該公司專注於為製藥和生物技術行業提供高質量的包裝和輸送解決方案，生產用於疫苗、生物製劑和其他可注射療法的主要藥物包裝組件和專用藥物輸送設備。西氏以其保持無菌性和與敏感藥物配方兼容的彈性密封件、密封圈和聚合物組件而聞名。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了組件製造，西氏還提供工程化輸送系統和產品生命週期支持服務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>TJX: Retail’s Apex Predator Feasts on Inflation</li>
<li>MarketBeat Week in Review – 06/08 - 06/12</li>
<li>SpaceX Rings the Bell and Shatters Every Record</li>
<li>Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過西氏醫藥服務</li>
<li>TJX：零售業的頂級掠食者在通貨膨脹中大快朵頤</li>
<li>MarketBeat 週迴顧 – 06/08 - 06/12</li>
<li>SpaceX 敲響鐘聲，打破所有記錄</li>
<li>Adobe 股票剛剛變得更便宜——華爾街是否忽視了這個故事？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮西氏醫藥服務之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而西氏醫藥服務並不在名單上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Van ECK Associates Corp Decreases Stock Holdings in West Pharmaceutical Services, Inc. $WST

Market Beat

YieldMax JPM Option Income Strategy ETF

Defiance Daily Target 2X Long JPM ETF

諾底亞銀行(ADR)

Evercore

巴克萊銀行

標普 500 指數

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Van ECK Associates Corp 減少了其在西氏醫藥服務公司（West Pharmaceutical Services, Inc.）的股票持有量 $WST